<DOC>
	<DOCNO>NCT02384317</DOCNO>
	<brief_summary>This pilot study test safety , tolerability , efficacy CCX168 reduce proteinuria patient Immunoglobulin A nephropathy persistent proteinuria despite supportive therapy maximally tolerate RAAS blocker .</brief_summary>
	<brief_title>Open-Label Study Evaluate Safety Efficacy CCX168 Subjects With Immunoglobulin A Nephropathy Stable RAAS Blockade</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin A</mesh_term>
	<criteria>Key Diagnosis Immunoglobulin A nephropathy estimate glomerular filtration rate &gt; 60 mL/min/1.73 m2 Proteinuria ( first morning urinary protein : creatinine ratio &gt; 1g/g creatinine ) Key Severe renal disease Pregnant nursing Proteinuria &gt; 8g/g creatinine &gt; 8g/day Systemic manifestation HenochSchonlein purpura within 2 year prior Patients Immunoglobulin A nephropathy deem secondary underlying disease Biopsy report severe crescentic Immunoglobulin A nephropathy History treatment glucocorticoid , cyclophosphamide , azathioprine , mycophenolate mofetil , biologic immunomodulatory agent 24 week prior History clinically significant cardiac condition History cancer within 5 year prior Any infection require antibiotic treatment clear prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>